Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Tesla Debuts Full SelfDriving Supervised in China as Local EV Competition Intensifies Intuit Faces Mixed Analyst Perspectives Amid Market Dynamics Wall Street Ends Mixed Oil Prices Slide on Iran Deal Hopes Micron Gains 56 GlobalFoundries Drops 9 World Bank Data Suggests Automation Could Threaten 69 of Jobs in India Goldman Sachs Shifts Focus Away from Apple Card Partnership Stock Movement Draws Market Attention OPRX Q1 2026 Earnings Massive EPS Beat Driven by Strong Operational Performance Resideo Technologies REZI Q1 2026 Earnings EPS Beats Estimates by 533 Stock Edges Lower Estee Lauder EL Q1 2026 Earnings Strong EPS Beat Drives DoubleDigit Stock Surge Pasithea Therapeutics KTTA Q1 2026 Earnings NarrowerthanExpected Loss Drives Positive Market Reaction Udemy Q1 2026 Earnings Deep EPS Miss Overshadows Quiet Market Interactive Brokers Group IBKR Gains Ground as Uptrend Continues Cheniere Energy Partners CQP Holds Steady Near 61 Showing Resilience in Quiet Trading ACM Research ACMR Gains 25 as Stock Approaches Key Resistance Level Helios Technologies HLIO Surges 387 Breaking Above Key Support Zone GlobalFoundries Launches Quantum Technology Solutions Unit with 375M CHIPS Award Chemical Incident at Washington Paper Mill Leaves Fatalities Missing Workers Nippon Dynawave Faces Safety Scrutiny Newcleo Targets Nasdaq Listing With 24 Billion Valuation in Nuclear Energy Play Trump Asks Supreme Court to Intervene in TikTok Ban Market Implications WaterBridge Infrastructure LLC WBI Q4 2025 Earnings EPS Surges Past Estimates Despite Revenue Gap PHGE Q4 2025 Earnings Severe EPS Miss as BiomX Continues Clinical Development MGRX Q3 2025 Earnings EPS Surprises with 069 Loss as Revenue Remains Undisclosed OXLCN Q4 2025 Earnings Preferred Stock Reports Slight EPS Miss Amid Steady Portfolio Performance KOSS Q1 2026 Earnings Negative EPS as Company Faces Continued Headwinds Iovance Biotherapeutics Q1 2026 Earnings EPS Misses Estimates but Stock Rises on Operational Momentum